Skip to main content

Upper Limb Spasticity

2
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
1
1
BOTOX®Phase 41 trial
ABBV-950Phase 11 trial
Botulinum toxin type A, BoNT-AN/A1 trial
Active Trials
NCT00945295Completed31Est. May 2012
NCT05956509Terminated1Est. Jun 2024
NCT00430196Completed135Est. Sep 2006
Ipsen
IpsenChina - Tianjin
1 program
AboBoNT-APHASE_41 trial
Active Trials
NCT04936542Completed464Est. Aug 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenAboBoNT-A
AbbVieBOTOX®
AbbVieABBV-950
AbbVieBotulinum toxin type A, BoNT-A

Clinical Trials (4)

Total enrollment: 631 patients across 4 trials

NCT04936542IpsenAboBoNT-A

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

Start: Jun 2021Est. completion: Aug 2025464 patients
Phase 4Completed
NCT00430196AbbVieBOTOX®

BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity

Start: Dec 2003Est. completion: Sep 2006135 patients
Phase 4Completed
NCT05956509AbbVieABBV-950

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

Start: Jan 2024Est. completion: Jun 20241 patients
Phase 1Terminated
NCT00945295AbbVieBotulinum toxin type A, BoNT-A

Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity

Start: Jan 2009Est. completion: May 201231 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.